시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 다발성 경화증 치료 시장 보고서(2025년)
Multiple Sclerosis Treatment Global Market Report 2025
상품코드 : 1769665
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,471,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,354,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,236,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

다발성 경화증 치료 시장 규모는 향후 수년간 안정된 성장이 예상될 예정입니다. 이 예상 성장은 새로운 단일클론 항체 승인 증가, 개인화 치료에 대한 수요 증가, 신경퇴행성 질환 관리에 대한 집중도 강화, 다발성 경화증 치료에서의 원격의료 활용 확대, 최소 침습적 치료 접근법으로의 전환 등이 주요 요인으로 꼽힙니다. 예측 기간에 예상되는 주목할 만한 동향으로는 원격 모니터링 기술의 발전, 재수초화 치료법 개발, 장-뇌 축 접근법 탐구, 디지털 바이오마커 통합, 디지털 치료의 혁신 등이 있습니다.

신경계 질환의 유병률이 증가함에 따라 다발성 경화증 치료제 시장이 성장할 것으로 예상됩니다. 신경계 질환은 뇌, 척수 및 신경에 영향을 미치는 질환으로, 운동, 의사소통, 행동 또는 신체 기능에 문제를 일으킵니다. 이 신경계 질환의 증가세는 주로 고령화 인구 증가에 기인하며, 기대 수명의 연장으로 알츠하이머병과 같은 노화 관련 질환의 위험이 높아지기 때문입니다. 다발성 경화증 치료는 면역 체계를 조절하여 염증을 줄이고 신경 손상을 최소화하며 증상을 완화함으로써 환자의 삶의 질을 향상시키는 데 중요한 역할을 합니다. 예를 들어, 2023년 10월, 영국에 본사를 둔 국가 신경학 학회 연합체인 세계 신경학 연맹(World Federation of Neurology)은 전 세계 인구의 40% 이상이 현재 어떤 형태의 신경학적 질환을 앓고 있으며, 이 수치는 2050년까지 거의 두 배로 증가할 것으로 예상된다고 보고했습니다. 그 결과, 신경학적 질환의 유병률 증가가 다발성 경화증 치료제 시장의 확장에 크게 기여하고 있습니다.

다발성 경화증 치료 분야에서 활동하는 기업들은 치료 결과와 효능을 개선하기 위해 단일 클론 항체 의약품과 같은 첨단 치료법 개발에 점점 더 집중하고 있습니다. 단일 클론 항체는 특정 항원을 표적으로 하는 실험실에서 제작된 분자로, 다발성 경화증의 경우 염증을 최소화하고 면역 세포의 공격을 막아 신경 섬유를 보호함으로써 질병의 진행을 늦추는 역할을 합니다. 예를 들어, 2024년 2월, 인도 제약 회사인 Roche Pharma India는 다발성 경화증 치료제인 Ocrevus (Ocrelizumab)를 출시했습니다. 이 의약품은 CD20 양성 B 세포를 표적으로 하여 염증과 신경 손상을 감소시킵니다. 이 약물은 재발성 및 원발성 다발성 경화증에 대해 승인된 최초의 치료제로, 재발률을 크게 낮추고 장애의 진행을 늦추는 효과가 있으며, 1년에 2회 주입으로 투여할 수 있는 장점도 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별, 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Multiple sclerosis (MS) treatment encompasses medical strategies and therapies designed to manage symptoms, slow disease progression, and enhance the quality of life for individuals with MS, a chronic autoimmune condition that impacts the central nervous system. These treatments include disease-modifying therapies (DMTs) and symptomatic interventions that address issues such as fatigue, muscle spasms, and mobility difficulties. The primary goal of MS treatment is to support neurological function and improve patients' overall well-being.

Key types of MS treatments include immunomodulators, corticosteroids, symptomatic therapies, monoclonal antibodies, and oral medications. Immunomodulators, such as interferon beta and glatiramer acetate, work by modifying immune system activity to reduce inflammation and prevent relapses. MS-related conditions include clinically isolated syndrome, relapsing-remitting MS, primary progressive MS, and secondary progressive MS. Treatment delivery methods include oral, injectable, and intravenous routes, and these are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The treatments cater to various end users, including hospitals, specialty clinics, homecare settings, and others.

The multiple sclerosis treatment market research report is one of a series of new reports from The Business Research Company that provides multiple sclerosis treatment market statistics, including the multiple sclerosis treatment industry's global market size, regional shares, competitors with the multiple sclerosis treatment market share, detailed multiple sclerosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the multiple sclerosis treatment industry. This multiple sclerosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The multiple sclerosis treatment market size has grown strongly in recent years. It will grow from $24.86 billion in 2024 to $26.13 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. This growth during the historical period was driven by heightened awareness of early MS symptoms, expanded access to disease-modifying therapies, rising incidence of autoimmune disorders, improved neurological healthcare infrastructure, and growing use of immunomodulatory drugs.

The multiple sclerosis treatment market size is expected to see steady growth in the next few years. It will grow to $31.55 billion in 2029 at a compound annual growth rate (CAGR) of 4.8%. This anticipated growth is attributed to increasing approvals of novel monoclonal antibodies, heightened demand for personalized MS treatments, enhanced focus on managing neurodegenerative diseases, wider use of telemedicine in MS care, and a shift toward minimally invasive treatment approaches. Notable trends expected in the forecast period include advancements in remote monitoring technologies, the development of remyelination therapies, exploration of gut-brain axis approaches, the integration of digital biomarkers, and innovation in digital therapeutics.

The increasing prevalence of neurological disorders is anticipated to drive the growth of the multiple sclerosis treatment market. Neurological disorders are conditions that impact the brain, spinal cord, and nerves, resulting in challenges with movement, communication, behavior, or bodily functions. This rise in neurological conditions is primarily attributed to an aging population, as longer life expectancies heighten the risk of age-related disorders like Alzheimer's disease. Multiple sclerosis treatments play a crucial role in managing such neurological issues by modulating the immune system to reduce inflammation, minimize nerve damage, and alleviate symptoms, ultimately enhancing patients' quality of life. For example, in October 2023, the World Federation of Neurology, a UK-based organization representing national neurological societies, reported that over 40% of the global population is currently affected by some form of neurological condition, with this figure expected to nearly double by 2050. As a result, the rising prevalence of neurological disorders is significantly contributing to the expansion of the multiple sclerosis treatment market.

Companies operating in the multiple sclerosis treatment space are increasingly focusing on the development of advanced therapies, such as monoclonal antibody drugs, to improve treatment outcomes and efficacy. Monoclonal antibodies are lab-engineered molecules designed to target specific antigens, and in the context of multiple sclerosis, they work by minimizing inflammation and protecting nerve fibers from immune cell attacks, thereby slowing disease progression. For instance, in February 2024, Roche Pharma India, an Indian pharmaceutical company, launched Ocrevus (Ocrelizumab) to treat multiple sclerosis. This drug specifically targets CD20-positive B cells to reduce inflammation and nerve damage. It is the first therapy approved for both relapsing and primary progressive forms of MS and is known to significantly lower relapse rates and slow disability progression with the added benefit of biannual infusions.

In March 2024, Juvise Pharmaceuticals, a pharmaceutical company based in France, acquired a multiple sclerosis drug from Actelion Pharmaceuticals Ltd. for an undisclosed amount. This acquisition aims to broaden Juvise Pharmaceuticals' neurology portfolio beyond the US and Canadian markets, while also involving financial support from Bpifrance and Pemberton to back its future growth strategies. Actelion Pharmaceuticals Ltd., based in Switzerland, is a pharmaceutical company actively engaged in multiple sclerosis treatment development.

Major players in the multiple sclerosis treatment market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Biogen Inc., UCB S.A., Mallinckrodt Pharmaceuticals, Acorda Therapeutics Inc., Adamas Pharmaceuticals Inc., Mapi Pharma Ltd., TG Therapeutics Inc., Atara Biotherapeutics Inc.

North America was the largest region in the multiple sclerosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in multiple sclerosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the multiple sclerosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The multiple sclerosis treatment market consists of sales of products including disease-modifying therapies, synthetic polypeptides, cannabinoid-based therapies, interferon beta products, and plasma exchange. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Multiple Sclerosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multiple sclerosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for multiple sclerosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multiple sclerosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Subsegments

Table of Contents

1. Executive Summary

2. Multiple Sclerosis Treatment Market Characteristics

3. Multiple Sclerosis Treatment Market Trends And Strategies

4. Multiple Sclerosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Multiple Sclerosis Treatment Growth Analysis And Strategic Analysis Framework

6. Multiple Sclerosis Treatment Market Segmentation

7. Multiple Sclerosis Treatment Market Regional And Country Analysis

8. Asia-Pacific Multiple Sclerosis Treatment Market

9. China Multiple Sclerosis Treatment Market

10. India Multiple Sclerosis Treatment Market

11. Japan Multiple Sclerosis Treatment Market

12. Australia Multiple Sclerosis Treatment Market

13. Indonesia Multiple Sclerosis Treatment Market

14. South Korea Multiple Sclerosis Treatment Market

15. Western Europe Multiple Sclerosis Treatment Market

16. UK Multiple Sclerosis Treatment Market

17. Germany Multiple Sclerosis Treatment Market

18. France Multiple Sclerosis Treatment Market

19. Italy Multiple Sclerosis Treatment Market

20. Spain Multiple Sclerosis Treatment Market

21. Eastern Europe Multiple Sclerosis Treatment Market

22. Russia Multiple Sclerosis Treatment Market

23. North America Multiple Sclerosis Treatment Market

24. USA Multiple Sclerosis Treatment Market

25. Canada Multiple Sclerosis Treatment Market

26. South America Multiple Sclerosis Treatment Market

27. Brazil Multiple Sclerosis Treatment Market

28. Middle East Multiple Sclerosis Treatment Market

29. Africa Multiple Sclerosis Treatment Market

30. Multiple Sclerosis Treatment Market Competitive Landscape And Company Profiles

31. Multiple Sclerosis Treatment Market Other Major And Innovative Companies

32. Global Multiple Sclerosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Multiple Sclerosis Treatment Market

34. Recent Developments In The Multiple Sclerosis Treatment Market

35. Multiple Sclerosis Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기